5-Day Rally Sends Eli Lilly Stock Up 14%
Eli Lilly (LLY) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 14% return. The company has gained about $101 Bil in value over the last 5 days, with its current market capitalization at about $831 Bil. The stock remains 20.6% above its value at the end of 2024. This compares with year-to-date returns of 15.6% for the S&P 500.
LLY provides innovative pharmaceuticals globally, including treatments for cancer, rheumatoid arthritis, and autoimmune diseases such as psoriasis and ankylosing spondylitis. After this rally, is LLY still a buy – or is it time to lock in gains? Deep dive with Buy or Sell LLY.
A single stock can be risky, but there is a huge value to a broader, diversified approach we take with the Trefis High Quality Portfolio. We go beyond just equities. Is a portfolio of 10% commodities, 10% gold, and 2% crypto in addition to equities and bonds likely to return more during the next 1-3 years, and protect you better if markets crash 20%? We have crunched the numbers.
Comparing LLY Stock Returns With The S&P 500
- The Next Big Rally in Ford Motor Stock Could Start Like This
- The Risk Factors to Watch Out For in NVIDIA Stock
- Intuitive Surgical Stock Now 16% Cheaper, Time To Buy
- AT&T Stock Pays Out $85 Bil – Investors Take Note
- Intel Stock Pays Out $92 Bil – Investors Take Note
- Comcast Stock Capital Return Hits $44 Bil
The following table summarizes the return for LLY stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | LLY | S&P 500 |
|---|---|---|
| 1D | 2.1% | 0.4% |
| 5D (Current Streak) | 13.8% | -1.4% |
| 1M (21D) | 9.7% | 1.2% |
| 3M (63D) | 44.8% | 7.2% |
| YTD 2025 | 20.6% | 15.6% |
| 2024 | 33.3% | 23.3% |
| 2023 | 60.9% | 24.2% |
| 2022 | 34.3% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 41 S&P constituents with 3 days or more of consecutive gains and 62 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 27 | 44 |
| 4D | 3 | 8 |
| 5D | 11 | 2 |
| 6D | 0 | 3 |
| 7D or more | 0 | 5 |
| Total >=3 D | 41 | 62 |
Key Financials for Eli Lilly (LLY)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $34.1 Bil | $45.0 Bil |
| Operating Income | $10.8 Bil | $17.5 Bil |
| Net Income | $5.2 Bil | $10.6 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $12.7 Bil | $15.6 Bil |
| Operating Income | $5.4 Bil | $7.1 Bil |
| Net Income | $2.8 Bil | $5.7 Bil |
While LLY stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.